DIOSynVax

What DIOSynVax does

DIOSynVax is a Cambridge, UK-based clinical-stage biotechnology company spun out from the University of Cambridge that develops vaccines using a proprietary AI-driven Vaccine Antigen Payload (VAP) design platform. The platform combines computational biology with in vitro and in vivo validation to engineer synthetic antigens — entirely in silico — that target conserved regions across entire virus families rather than single strains. Its lead asset, pEVAC-PS (PanSarCoV), is a pan-sarbecovirus vaccine candidate designed to provide broad protection against SARS-CoV-2, SARS, and related bat coronaviruses; it completed Phase I human trials in 39–49 healthy volunteers with results published in the Journal of Infection in June 2026, and a Phase II efficacy trial in approximately 200 participants is now underway. The same VAP design platform is being extended to develop pan-influenza and Ebola vaccine candidates, delivered initially via a needle-free DNA format using PharmaJet's Tropis system.

The company is privately held (DIOSynVax Ltd.), with 1–10 employees, and has raised approximately $46.5M across three disclosed rounds: a 2020 Parkwalk Advisors seed, a 2020 Innovate UK grant, and a $42M CEPI-led round in March 2022. Core partners and collaborators include the University of Cambridge (founding institution), the University of Southampton (trial sponsor via University Hospital Southampton NHS Foundation Trust), CEPI, the University of Kent, the University of Regensburg, PharmaJet, and NIHR Clinical Research Facilities in Southampton and Cambridge. The intended go-to-market is licensing the VAP platform and vaccine candidates to global health authorities, governments, and pharmaceutical partners rather than direct commercial sales, and the company is pre-revenue with no disclosed pricing or licensing economics.

Name

DIOSynVax

Legal name

DIOSynVax Ltd.

Website

https://diosvax.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Biopharmaceutical Vaccine Development

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industries

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF), Seasonal & Endemic Vaccines (e.g., Influenza) (HLAIAEAD)

Keywords

• Vaccine antigen design
• Computational vaccine development
• AI-designed vaccines
• Universal coronavirus vaccine
• Biotech vaccine platform

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

1. Vaccine Development and Licensing: DIOSynVax develops novel vaccines through clinical trials and plans to commercialize through licensing agreements with pharmaceutical companies, government contracts, and potentially direct sales to healthcare systems. The company raised $42 million in funding to support development of coronavirus vaccines and expansion to other pathogens including influenza and Ebola.
2. Technology Platform Licensing: The company's AI-driven vaccine antigen design platform (VAP design) could be licensed to other vaccine developers for targeting different virus families, representing a potential additional revenue stream.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

DIOSynVax develops AI-designed vaccines using computational biology to engineer Vaccine Antigen Payloads (VAP) that target conserved regions across entire virus families. Its lead candidate, pEVAC-PS, is a pan-sarbecovirus DNA vaccine in clinical trials, and the same AI platform is being extended to develop universal influenza and Ebola vaccines.

Product overview

DIOSynVax offers a unified platform approach centered on its proprietary Vaccine Antigen Payload (VAP) Design Platform, which uses computational biology and AI to design vaccine antigens. The primary product application is the pEVAC-PS (also called PanSarCoV) universal coronavirus vaccine, which completed Phase I human trials in 2026. The VAP platform is being extended to develop pan-influenza and Ebola vaccine candidates.

Differentiator

Problem solved

Functional benefit

Products and services

• pEVAC-PS (PanSarCoV) Universal Coronavirus Vaccine AI-designed universal sarbecovirus vaccine candidate that uses a needle-free DNA delivery system (PharmaJet Tropis) to target conserved regions across SARS-CoV-2, SARS, and related bat coronaviruses. The active component is a synthetic antigen designed entirely in silico; it completed Phase I trials and a Phase II trial in approximately 200 participants was announced in 2026.
• Vaccine Antigen Payload (VAP) Design Platform Proprietary computational biology platform that customises vaccine antigen design to maximise protection against existing and future viruses. Combines computational biology with in vitro and in vivo validation, selecting optimal Vaccine Antigen Payload candidates while growing a reservoir of data that continually improves designs; intended to be licensed to vaccine developers targeting different virus families.

Quantifiable outcome

• First AI-designed vaccine to pass Phase I human safety trial in 39-49 healthy volunteers
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• University of CambridgecoreStrategic or Co-development PartnerUniversity of Cambridge is the founding institution of DIOSynVax as a spinout company. Researchers from the university collaborated with the company to develop the AI-designed universal coronavirus vaccine technology.
• University of SouthamptoncoreStrategic or Co-development PartnerUniversity of Southampton researchers collaborated on the AI-designed vaccine development. The Phase I trial was sponsored by University Hospital Southampton NHS Foundation Trust.
• CEPI (Coalition for Epidemic Preparedness Innovations)coreStrategic or Co-development PartnerCEPI is listed as a collaborator on DIOSynVax's website, working to advance innovative vaccine solutions and protect global health.
• University of KentminorStrategic or Co-development PartnerListed as a collaborator on DIOSynVax's website, contributing to the partnership network advancing vaccine solutions.
• University of RegensburgminorStrategic or Co-development PartnerListed as a collaborator on DIOSynVax's website, part of the international research network supporting vaccine development.
• PharmaJetcoreTechnology or IntegrationPharmaJet provides the Tropis needle-free jet injector system used for delivery of DIOSynVax's DNA vaccine candidate, enabling needle-free immunization.
• NIHR Clinical Research FacilitiescoreStrategic or Co-development PartnerPhase I and Phase II clinical trials conducted at NIHR Clinical Research Facilities in Southampton and Cambridge, UK.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/diosvax

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DIOSynVax